Camrelizumab, formerly known as SHR-1210, represents a significant advancement in tumor immunotherapy , functioning as a antibody that targets the programmed death-1 receptor. This control protein, expressed on immune cells , normally dampens antitumor immune responses, allowing malignant tissues